ΔF508 heterozygosity and asthma (multiple letters) [1]

Lancet

Volumn 352, Issue 9132, 1998, Pages 984-987

  Swift, M ^a   Su, Y ^a   Warner, J O ^a   Lowenfels, A B ^a   Maisonneuve, P ^a   Palys, B ^a   Schoni, M H ^a   Redemann, B ^a   Dahl, M ^a   Tybjaerg Hansen, A ^a   Lange, P ^a   Nordestgaard, B G ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CFTR PROTEIN, HUMAN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR DELTA F508; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ALLELE; ASTHMA; CYSTIC FIBROSIS; GENE MUTATION; HETEROZYGOSITY; HUMAN; LETTER; PRIORITY JOURNAL; GENETICS; HETEROZYGOTE; MUTATION; NOTE;

ASTHMA; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HETEROZYGOTE; HUMANS; MUTATION;

EID: 0032547456     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)00017-8     Document Type: Letter

References (3)

1. M Dahl A Tybjaerg P Lange BG Nordestgaard ΔF508 heterozygosity in cystic fibrosis and susceptibility to asthma Lancet 351 1998 1911 1913
2. SA Schroeder DM Gaughan M Swift Protection against bronchial asthma by CFTR ΔF508 mutation: a heterozygote advantage in cystic fibrosis Nat Med 1 1995 703 705
3. M Swift LL Kupper CL Chase Effective testing of gene-disease associations Am J Hum Genet 47 1990 266 274